Insulin (non-diabetic use)

Pharmaceutical insulin, misused in bodybuilding by people without diabetes. No controlled evidence supports any safe or effective use in that context.

Insulin drives glucose, amino acids and creatine into muscle cells and simultaneously blocks fat breakdown. That combination is why it is used non-medically as an anabolic adjunct: it is a genuinely powerful nutrient-partitioning hormone. It is also why it is the single most immediately dangerous compound in this catalogue. Every other drug here can harm you over months or years. Insulin can kill a healthy person in an afternoon, because the same mechanism that pushes glucose into muscle can drop blood sugar low enough to cause seizure, brain injury and death, and it does so on a timescale measured in tens of minutes.

Insulin's anabolic signaling is real physiology; that is where the legitimate evidence ends. There are no trials of non-diabetic physique use and never will be — the dose-error consequence forecloses the study design.

• Insulin is a life-saving, extensively evidenced medicine for diabetes. That evidence is about replacing a hormone someone lacks, and it says nothing about giving it to a person whose pancreas works normally. Note that older human insulins such as regular and NPH are sold without a prescription in much of the US while analogues generally are not — availability is not a safety signal.
• There is no trial of insulin for muscle building in healthy non-diabetic people. The literature that does exist in this population is a case-report and toxicology literature.
• Published case reports and series document severe hypoglycaemia, coma, permanent hypoxic brain injury and death in bodybuilders using insulin, including in experienced users following widely circulated protocols.
• Insulin is also a recognised agent in deliberate self-harm and in homicide, which is a reflection of how reliably lethal it is in a person without diabetes.
• Some physiological studies show insulin suppresses muscle protein breakdown, but the effect plateaus at levels the body reaches after an ordinary meal — meaning the theoretical anabolic ceiling is reached without injecting anything.

Onset and duration vary by preparation, from rapid-acting analogues that act within 15 minutes and peak around an hour, to long-acting basal insulins lasting a full day. The rapid-acting types are the ones used non-medically and the ones responsible for most reported harm, because the window between effect and crisis is short. Critically, the duration of a hypoglycaemic episode can outlast a single sugary drink, so treating a crash once is not the same as it being over — rebound is a documented cause of death after apparent recovery.

Severe hypoglycemia can rapidly cause seizures, brain injury, or death — bodybuilding's documented insulin fatalities are exactly this failure. This is among the most acutely dangerous practices covered anywhere in this catalog. Insulin is WADA-prohibited in sport without an applicable medical exemption.

• Anyone without diagnosed diabetes and a prescribing clinician — which is the entire non-medical use case
• Anyone who trains or sleeps alone
• Anyone who drinks alcohol
• Anyone with a history of eating disorder or self-harm
• Anyone with kidney or liver impairment, which unpredictably prolongs its action

• Alcohol — impairs the liver's ability to release glucose, and is present in a large share of fatal cases.
• Any other glucose-lowering agent, including metformin and, increasingly, GLP-1 agonists.
• Beta-blockers, which mask the early warning signs of a crash.
• Fasted training or a missed meal, which is the most common precipitant in reported cases.
• Anabolic steroids and growth hormone, which alter insulin sensitivity and make dose responses unpredictable.

• Blood glucose, measured with an actual meter, not by feel. Symptoms are unreliable and blunt with repeated lows.
• Awareness of hypoglycaemia symptoms — which fade with repeated exposure, a phenomenon called hypoglycaemia unawareness that makes continued use progressively more dangerous.
• Potassium, since insulin drives it into cells and severe hypokalaemia can cause fatal arrhythmia.
• Never being alone. The single most consistent factor in fatal cases is that nobody was there when consciousness was lost.

For someone without diabetes, stopping non-medical insulin has no withdrawal syndrome — blood sugar regulation returns to normal immediately because the pancreas was working the whole time. Anyone who has had a severe hypoglycaemic episode with loss of consciousness needs medical assessment, because brain injury from a severe crash is not always obvious afterwards. Anyone prescribed insulin for diabetes must never stop it without their clinician; that is a different situation entirely and stopping is life-threatening.

US: a prescription pharmaceutical in its common formulations. Legality of a product is not safety of a practice; this entry exists because the names circulate, not to normalize the use.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• A systematic review and meta-analysis comparing outcomes between using subcutaneous insulin and continuous insulin infusion in managing adult patients with diabetic ketoacidosis
  BMC Endocr Disord, 2024
• Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials
  Front Endocrinol (Lausanne), 2024
• Exercise and Insulin Resistance Markers in Children and Adolescents With Excess Weight: A Systematic Review and Network Meta-Analysis
  JAMA Pediatr, 2023

Not auto-graded. This entry covers several different drugs, or a use the published research was never about, so no single letter honestly describes it. The reading below is real literature — read it against what this page says, not as a score.

• The role of hormones in muscle hypertrophyPhys Sportsmed · 2018
• Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statementEndocr Rev · 2014
• InsulinHandb Exp Pharmacol · 2010
• Growth hormoneHandb Exp Pharmacol · 2010
• Gene dopingInt J Sports Med · 2006
• Strong diabetesBMJ Case Rep · 2009
• Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detectionAnal Bioanal Chem · 2013
• IGF-I abuse in sportCurr Drug Abuse Rev · 2009
• The many faces of testosteroneClin Interv Aging · 2007
• Protein quantification relevant to antidopingBioanalysis · 2020
• Growth hormone, IGF-I and insulin and their abuse in sportBr J Pharmacol · 2008
• Strong diabetesBr J Sports Med · 2007